PMID- 25557723 OWN - NLM STAT- MEDLINE DCOM- 20160524 LR - 20220408 IS - 1098-2744 (Electronic) IS - 0899-1987 (Linking) VI - 55 IP - 1 DP - 2016 Jan TI - Expression and prognostic role of ubiquitination factor E4B in primary hepatocellular carcinoma. PG - 64-76 LID - 10.1002/mc.22259 [doi] AB - Ubiquitination factor E4B (UBE4B) has been speculated to have contradictory functions upon tumorigenesis as an oncogene or tumor suppressor in different types of cancers. We investigated the expression and prognostic role of UBE4B in primary hepatocellular carcinoma (HCC) using cell lines and 149 archived HCC samples. Correlation between the functions of UBE4B in HCC was also explored. We used human HCC cell lines (HepG2, Hep3B, SK-Hep1, Huh7, SMMC-7721, BEL-7402) and a normal hepatocyte cell line (LO2) along with HCC samples from patients who had undergone resection for HCC previously at our hospital. A battery of methods (real-time quantitative polymerase chain reaction; Western blotting; immunohistochjemical analyses; cell proliferation and colony formation assays; cell migration and cell invasion assays) were employed to assess various aspects of UBE4B.We found that UBE4B expression was upregulated aberrantly at mRNA and protein levels in human primary HCC tissues. Amplified expression of UBE4B was highly correlated with poor outcome. Silencing of UBE4B expression by siRNA inhibited the proliferation, colony formation, migration and invasion of HCC cells in vitro, and resulted in significant apoptosis that was associated with downregulation of expression of Bcl-2 and upregulation of expression of total p53, p-p53, Bax and Cleaved-Caspase3 in HCC cells. Our findings suggested that UBE4B might have an oncogenic role in human primary HCC, and that it could be used as a prognostic marker (as well as a potential molecular target) for the treatment of HCC. CI - (c) 2015 Wiley Periodicals, Inc. FAU - Zhang, Xiao-Fei AU - Zhang XF AD - State Key Laboratory of Oncology in Southern China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China. AD - Department of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, People's Republic of China. FAU - Pan, Qiu-Zhong AU - Pan QZ AD - State Key Laboratory of Oncology in Southern China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China. AD - Department of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, People's Republic of China. FAU - Pan, Ke AU - Pan K AD - State Key Laboratory of Oncology in Southern China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China. AD - Department of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, People's Republic of China. FAU - Weng, De-Sheng AU - Weng DS AD - State Key Laboratory of Oncology in Southern China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China. AD - Department of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, People's Republic of China. FAU - Wang, Qi-Jing AU - Wang QJ AD - State Key Laboratory of Oncology in Southern China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China. AD - Department of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, People's Republic of China. FAU - Zhao, Jing-Jing AU - Zhao JJ AD - State Key Laboratory of Oncology in Southern China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China. AD - Department of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, People's Republic of China. FAU - He, Jia AU - He J AD - State Key Laboratory of Oncology in Southern China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China. AD - Department of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, People's Republic of China. FAU - Liu, Qing AU - Liu Q AD - State Key Laboratory of Oncology in Southern China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China. AD - Department of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, People's Republic of China. FAU - Wang, Dan-Dan AU - Wang DD AD - State Key Laboratory of Oncology in Southern China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China. AD - Department of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, People's Republic of China. FAU - Jiang, Shan-Shan AU - Jiang SS AD - State Key Laboratory of Oncology in Southern China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China. AD - Department of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, People's Republic of China. FAU - Zheng, Hai-Xia AU - Zheng HX AD - State Key Laboratory of Oncology in Southern China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China. AD - Department of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, People's Republic of China. FAU - Lv, Lin AU - Lv L AD - State Key Laboratory of Oncology in Southern China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China. AD - Department of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, People's Republic of China. FAU - Chen, Chang-Long AU - Chen CL AD - State Key Laboratory of Oncology in Southern China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China. AD - Department of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, People's Republic of China. FAU - Zhang, Hong-Xia AU - Zhang HX AD - State Key Laboratory of Oncology in Southern China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China. AD - Department of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, People's Republic of China. FAU - Xia, Jian-Chuan AU - Xia JC AD - State Key Laboratory of Oncology in Southern China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China. AD - Department of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, People's Republic of China. LA - eng PT - Journal Article DEP - 20150103 PL - United States TA - Mol Carcinog JT - Molecular carcinogenesis JID - 8811105 RN - 0 (Apoptosis Regulatory Proteins) RN - 0 (RNA, Small Interfering) RN - 0 (Tumor Suppressor Proteins) RN - EC 2.3.2.23 (Ubiquitin-Protein Ligase Complexes) RN - EC 2.3.2.27 (UBE4B protein, human) RN - EC 2.3.2.27 (Ubiquitin-Protein Ligases) SB - IM MH - Adult MH - Aged MH - Apoptosis/genetics MH - Apoptosis Regulatory Proteins/genetics/metabolism MH - Carcinoma, Hepatocellular/diagnosis/*genetics/*mortality/surgery MH - Cell Line, Tumor MH - Cell Proliferation MH - Female MH - *Gene Expression MH - Gene Knockdown Techniques MH - Gene Silencing MH - Humans MH - Immunohistochemistry MH - Liver Neoplasms/diagnosis/*genetics/*mortality/surgery MH - Male MH - Middle Aged MH - Neoplasm Grading MH - Neoplasm Staging MH - Prognosis MH - RNA Interference MH - RNA, Small Interfering/genetics MH - Risk Factors MH - Tumor Burden MH - Tumor Suppressor Proteins/*genetics/metabolism MH - Ubiquitin-Protein Ligase Complexes/*genetics/metabolism MH - Ubiquitin-Protein Ligases OTO - NOTNLM OT - UBE4B OT - apoptosis OT - hepatocellular carcinoma OT - oncogene OT - prognosis EDAT- 2015/01/06 06:00 MHDA- 2016/05/25 06:00 CRDT- 2015/01/06 06:00 PHST- 2014/06/21 00:00 [received] PHST- 2014/10/23 00:00 [revised] PHST- 2014/11/03 00:00 [accepted] PHST- 2015/01/06 06:00 [entrez] PHST- 2015/01/06 06:00 [pubmed] PHST- 2016/05/25 06:00 [medline] AID - 10.1002/mc.22259 [doi] PST - ppublish SO - Mol Carcinog. 2016 Jan;55(1):64-76. doi: 10.1002/mc.22259. Epub 2015 Jan 3.